Scilex and Oracle: Bullish Views, Potential Upsides Unveiled
- October 09th, 2023
- 797 views
HC Wainwright & Co. has initiated coverage on Scilex Holding Company (Nasdaq: SCLX), a pharmaceutical company, with a Buy rating and a price target of $12.
Closing at $1.57 on Friday, this price target suggests a substantial potential upside of $10.43 per share or approximately 664.33% for $SCLX, based on the financial services firm's view.
Separately, Evercore ISI Group upgraded Oracle Corporation (NYSE: ORCL), a multinational technology company, from In-Line to Outperform and raised the price target from $131 to $135.
With $ORCL closing at $109.96 on Friday, the projected new price target implies a potential upside of $25.04 per share or about 22.77%, according to the investment banking advisory firm's assessment.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FDA Grants Accelerated Approval to a New Breast Cancer Treatment
September 04th, 2026Signing Day Is Not the End of Recruiting
September 04th, 2026Treasury, IRS Move to End Tax-Exempt Status for Discriminatory Practices in Private Schools
September 03rd, 2026FDA Approves First Drug to Treat Alexander Disease
September 03rd, 2026How Coaching Staffs Evaluate Athletes Across a Season
September 03rd, 2026
Member Login